Fecal Microbiota Transplant for Relapsing Clostridium difficile Infection Using a Frozen Inoculum From Unrelated Donors: A Randomized, Open-Label, Controlled Pilot Study
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Recurrent Clostridium difficile infection (CDI) with poor response to standard antimicrobial therapy is a growing medical concern. We aimed to investigate the outcomes of fecal microbiota transplant (FMT) for relapsing CDI using a frozen suspension from unrelated donors, comparing colonoscopic and nasogastric tube (NGT) administration. METHODS: Healthy volunteer donors were screened and a frozen fecal suspension was generated. Patients with relapsing/refractory CDI were randomized to receive an infusion of donor stools by colonoscopy or NGT. The primary endpoint was clinical resolution of diarrhea without relapse after 8 weeks. The secondary endpoint was self-reported health score using standardized questionnaires. RESULTS: A total of 20 patients were enrolled, 10 in each treatment arm. Patients had a median of 4 (range, 2-16) relapses prior to study enrollment, with 5 (range, 3-15) antibiotic treatment failures. Resolution of diarrhea was achieved in 14 patients (70%) after a single FMT (8 of 10 in the colonoscopy group and 6 of 10 in the NGT group). Five patients were retreated, with 4 obtaining cure, resulting in an overall cure rate of 90%. Daily number of bowel movements changed from a median of 7 (interquartile range [IQR], 5-10) the day prior to FMT to 2 (IQR, 1-2) after the infusion. Self-ranked health score improved significantly, from a median of 4 (IQR, 2-6) before transplant to 8 (IQR, 5-9) after transplant. No serious or unexpected adverse events occurred. CONCLUSIONS: In our initial feasibility study, FMT using a frozen inoculum from unrelated donors is effective in treating relapsing CDI. NGT administration appears to be as effective as colonoscopic administration. CLINICAL TRIALS REGISTRATION: NCT01704937.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In a pilot open-label randomized trial, frozen FMT by nasogastric tube appeared to be as effective as colonoscopic administration in resolving CDIassociated diarrhea. 126”
From Key determinants of success in fecal microbiota transplantation: From microbiome to clinic (2023) · cites this paper as [126]
In the citing paper
“Youngster et al. conducted a randomized pilot study comparing upper and lower GI routes of FMT, and the report found a non-significant difference in cure rate between the two different administration methods.67”
From Fecal microbiota transplantation: Review and update (2019) · cites this paper as [67]
In the citing paper
“FMT has been examined in both young and old, patients with limited comorbidities as well as those considered to be immunocompromised,43 and the procedure has been shown to be safe, well-tolerated, and effective.”
From Update on Fecal Microbiota Transplantation 2015: Indications, Methodologies, Mechanisms, and Outlook (2015) · cites this paper as [43]
In the citing paper
“Furthermore, flares of FMT in patients with both UC and CD have been described,43, 75, 76 raising important questions around safety and the potential to worsen disease in some patients.”
From Update on Fecal Microbiota Transplantation 2015: Indications, Methodologies, Mechanisms, and Outlook (2015) · cites this paper as [43]
In the citing paper
“These include complications of endoscopy, such as perforation and bleeding, and side effects related to sedation, such as aspiration43.”
From Update on Fecal Microbiota Transplantation 2015: Indications, Methodologies, Mechanisms, and Outlook (2015) · cites this paper as [43]
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Ultra-high-throughput microbial community analysis on the Illumina HiSeq and MiSeq platforms
Caporaso, J. G., Lauber, C. L., Walters, W. A., Berg-Lyons, D., Huntley, J., Fierer, N., Owens, S. M., Betley, J., Fraser, L., Bauer, M., et al. (2012) · The ISME Journal · doi:10.1038/ismej.2012.8 · Cited by 8,839 · cited 1×
“DNA was extracted and the V4 region of the 16S gene was sequenced using an Illumina MiSeq (Illumina, San Diego, CA) as described previously [30].”
MethodDuodenal Infusion of Donor Feces for Recurrent Clostridium difficile
van Nood, E., Vrieze, A., Nieuwdorp, M., Fuentes, S., Zoetendal, E. G., de Vos, W. M., Visser, C. E., Kuijper, E. J., Bartelsman, J. F. W. M., Tijssen, J. G. P., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1205037 · Cited by 3,708
TROTTI, A., COLEVAS, A., SETSER, A., RUSCH, V, JAQUES, D., BUDACH, V, LANGER, C., MURPHY, B., CUMBERLIN, R., & COLEMAN, C. (2003) · Seminars in Radiation Oncology · doi:10.1016/s1053-4296(03)00031-6 · Cited by 2,569 · cited 1×
“0 [26] approved by the FDA and institutional review board (IRB).”
BackgroundFidaxomicin versus Vancomycin for Clostridium difficile Infection
Louie, T. J., Miller, M. A., Mullane, K. M., Weiss, K., Lentnek, A., Golan, Y., Gorbach, S., Sears, P., & Shue, Y.-K. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa0910812 · Cited by 1,585 · cited 1×
“recurrence exceeds 60% with antimicrobial therapy [3, 5–8].”
BackgroundClostridium difficile infection: new developments in epidemiology and pathogenesis
Rupnik, M., Wilcox, M. H., & Gerding, D. N. (2009) · Nature Reviews Microbiology · doi:10.1038/nrmicro2164 · Cited by 1,380 · cited 1×
“The emergence of a virulent strain of the organism (NAP1/BI/027) has been associated with even higher rates of treatment failure [9,10].”
BackgroundClostridium difficile— More Difficult Than Ever
Kelly, C. P., & LaMont, J. T. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0707500 · Cited by 1,313 · cited 1×
“In the United States the incidence of CDI has tripled over the last 15 years [3].”
BackgroundDecreased Diversity of the Fecal Microbiome in Recurrent Clostridium difficile–Associated Diarrhea
Chang, J. Y., Antonopoulos, D. A., Kalra, A., Tonelli, A., Khalife, W. T., Schmidt, T. M., & Young, V. B. (2008) · The Journal of Infectious Diseases · doi:10.1086/525047 · Cited by 1,010 · cited 1×
“Failure to reconstitute normal flora was shown to be a factor in severe, recurrent, and prolonged illness [13].”
BackgroundTreating Clostridium difficile infection with fecal microbiota transplantation
Bakken, J. S., Borody, T., Brandt, L. J., Brill, J. V., Demarco, D. C., Franzos, M. A., Kelly, C., Khoruts, A., Louie, T., Martinelli, L. P., et al. (2011) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2011.08.014 · Cited by 1,003 · cited 1×
“5 guidelines [26] by a relapse of CDI after having at least three episodes of mild-to-moderate CDI and failure of a 6-8 week taper with vancomycin with or without an alternative antibiotic, OR, at least two episodes of severe CDI resulting in hospitalization and associated with significant morbidity.”
BackgroundSelf-citationKassam, Z., Lee, C. H., Yuan, Y., & Hunt, R. H. (2013) · American Journal of Gastroenterology · doi:10.1038/ajg.2013.59 · Cited by 904 · cited 1×
“Another inhibiting factor is the fact that the available data are mostly based on retrospective case series and include only a single randomized trial [21,24,25] to date, making practitioners cautious about adopting FMT as a viable treatment alternative.”
BackgroundHamilton, M. J., Weingarden, A. R., Sadowsky, M. J., & Khoruts, A. (2012) · American Journal of Gastroenterology · doi:10.1038/ajg.2011.482 · Cited by 738 · cited 1×
“The work of Hamilton and Khoruts [28] was used as a guide for fecal manipulation, with the exception that all processes were carried out under ambient air, not nitrogen.”
Method
Research works printed but not linked: 1
- 2013, Clostridium difficile infection in children, JAMA Pediatr, 167, 567, 10.1001/jamapediatrics.2013.441 · DOI · Paper page
Cited by
McDonald, L. C., Gerding, D. N., Johnson, S., Bakken, J. S., Carroll, K. C., Coffin, S. E., Dubberke, E. R., Garey, K. W., Gould, C. V., Kelly, C., et al. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/cix1085 · Cited by 2,690
Kang, D.-W., Adams, J. B., Gregory, A. C., Borody, T., Chittick, L., Fasano, A., Khoruts, A., Geis, E., Maldonado, J., McDonough-Means, S., et al. (2017) · Microbiome · doi:10.1186/s40168-016-0225-7 · Cited by 1,391
European consensus conference on faecal microbiota transplantation in clinical practice
Cammarota, G., Ianiro, G., Tilg, H., Rajilić-Stojanović, M., Kump, P., Satokari, R., Sokol, H., Arkkila, P., Pintus, C., Hart, A., et al. (2017) · Gut · doi:10.1136/gutjnl-2016-313017 · Cited by 1,207
Meta-analysis of gut microbiome studies identifies disease-specific and shared responses
(2017) · doi:10.1038/s41467-017-01973-8 · Cited by 986
Self-citationFactors affecting the composition of the gut microbiota, and its modulation
Hasan, N., & Yang, H. (2019) · PeerJ · doi:10.7717/peerj.7502 · Cited by 755
van Prehn, J., Reigadas, E., Vogelzang, E. H., Bouza, E., Hristea, A., Guery, B., Krutova, M., Norén, T., Allerberger, F., Coia, J. E., et al. (2021) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.09.038 · Cited by 640
The microbiome of the urinary tract—a role beyond infection
Whiteside, S. A., Razvi, H., Dave, S., Reid, G., & Burton, J. P. (2015) · Nature Reviews Urology · doi:10.1038/nrurol.2014.361 · Cited by 633
Youngster, I., Russell, G. H., Pindar, C., Ziv-Baran, T., Sauk, J., & Hohmann, E. L. (2014) · JAMA · doi:10.1001/jama.2014.13875 · Cited by 629
“3) [11-89] 3 (3-5) [2-6] 10 (8-15) [6-30] 5 (5-7) [2-9] 4.”
Self-citationQuraishi, M. N., Widlak, M., Bhala, N., Moore, D., Price, M., Sharma, N., & Iqbal, T. H. (2017) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14201 · Cited by 617
“Frozen Costello 2015 [69] Lee 2016 (FMT) [24] Youngster 2014 (Both FMT arms) [71] Youngster 2014 [28] Subtotal (I^2=19.”
BackgroundKao, D., Roach, B., Silva, M., Beck, P., Rioux, K., Kaplan, G. G., Chang, H.-J., Coward, S., Goodman, K. J., Xu, H., et al. (2017) · JAMA · doi:10.1001/jama.2017.17077 · Cited by 615
“Physical functioning 45 (20-70) 35 (20-65)”
Fecal microbiota transplantation: Review and update
Wang, J.-W., Kuo, C.-H., Kuo, F.-C., Wang, Y.-K., Hsu, W.-H., Yu, F.-J., Hu, H.-M., Hsu, P.-I., Wang, J.-Y., & Wu, D.-C. (2019) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2018.08.011 · Cited by 576
Update on Fecal Microbiota Transplantation 2015: Indications, Methodologies, Mechanisms, and Outlook
Kelly, C. R., Kahn, S., Kashyap, P., Laine, L., Rubin, D., Atreja, A., Moore, T., & Wu, G. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.05.008 · Cited by 572
Cammarota, G., Masucci, L., Ianiro, G., Bibbò, S., Dinoi, G., Costamagna, G., Sanguinetti, M., & Gasbarrini, A. (2015) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13144 · Cited by 558
“60% respectively); however, the difference between the two treatment approaches was not significant.(26) In addition, this study did not include a non-FMT control group.”
ResultGut microbiota: A player in aging and a target for anti-aging intervention
Vaiserman, A. M., Koliada, A. K., & Marotta, F. (2017) · Ageing Research Reviews · doi:10.1016/j.arr.2017.01.001 · Cited by 465
Gut microbiota in autism and mood disorders
Mangiola, F. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i1.361 · Cited by 413
Factors Influencing the Gut Microbiota, Inflammation, and Type 2 Diabetes
Wen, L., & Duffy, A. (2017) · The Journal of Nutrition · doi:10.3945/jn.116.240754 · Cited by 412
Smillie, C. S., Sauk, J., Gevers, D., Friedman, J., Sung, J., Youngster, I., Hohmann, E. L., Staley, C., Khoruts, A., Sadowsky, M. J., et al. (2018) · Cell Host & Microbe · doi:10.1016/j.chom.2018.01.003 · Cited by 411
“processed and prepared as previously described (Youngster et al., 2014).”
BackgroundMethodInfluentialSelf-citationWeight Gain After Fecal Microbiota Transplantation
Alang, N., & Kelly, C. R. (2015) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofv004 · Cited by 403
“She improved and did not suffer a further CDI recurrence after FMT.”
BackgroundInfluentialGut microbiome and depression: what we know and what we need to know
Winter, G., Hart, R. A., Charlesworth, R. P. G., & Sharpley, C. F. (2018) · Reviews in the Neurosciences · doi:10.1515/revneuro-2017-0072 · Cited by 394
Antibiotic resistance in Enterobacteriaceae: mechanisms and clinical implications
Iredell, J., Brown, J., & Tagg, K. (2016) · BMJ · doi:10.1136/bmj.h6420 · Cited by 392
Hvas, C. L., Dahl Jørgensen, S. M., Jørgensen, S. P., Storgaard, M., Lemming, L., Hansen, M. M., Erikstrup, C., & Dahlerup, J. F. (2019) · Gastroenterology · doi:10.1053/j.gastro.2018.12.019 · Cited by 390
Fecal Microbiota Transplantation for Clostridium difficile Infection: A Systematic Review
Drekonja, D., Reich, J., Gezahegn, S., Greer, N., Shaukat, A., MacDonald, R., Rutks, I., & Wilt, T. J. (2015) · Annals of Internal Medicine · doi:10.7326/m14-2693 · Cited by 371
“Harms of FMT The 2 included RCTs reported mild adverse events attributed to FMT, including diarrhea, cramping, belching, nausea, abdominal pain, bloating, transient fever, and dizziness (11, 18).”
BackgroundInfluentialMullish, B. H., Quraishi, M. N., Segal, J. P., McCune, V. L., Baxter, M., Marsden, G. L., Moore, D. J., Colville, A., Bhala, N., Iqbal, T. H., et al. (2018) · Gut · doi:10.1136/gutjnl-2018-316818 · Cited by 332
Key determinants of success in fecal microbiota transplantation: From microbiome to clinic
Porcari, S., Benech, N., Valles-Colomer, M., Segata, N., Gasbarrini, A., Cammarota, G., Sokol, H., & Ianiro, G. (2023) · Cell Host & Microbe · doi:10.1016/j.chom.2023.03.020 · Cited by 331
Yu, E. W., Gao, L., Stastka, P., Cheney, M. C., Mahabamunuge, J., Torres Soto, M., Ford, C. B., Bryant, J. A., Henn, M. R., & Hohmann, E. L. (2020) · PLOS Medicine · doi:10.1371/journal.pmed.1003051 · Cited by 329
“difficile colitis [40], although appropriate caution should be taken when extrapolating from FMT outcomes in other disease conditions.”
BackgroundSelf-citationFecal Microbiota Transplantation: Current Applications, Effectiveness, and Future Perspectives
Choi, H. H., & Cho, Y.-S. (2016) · Clinical Endoscopy · doi:10.5946/ce.2015.117 · Cited by 318
“Although the role of FMT in primary and severe CDI has not been established, FMT is recommended in case of two or more recurrences of uncomplicated CDI.”
InfluentialVermeire, S., Joossens, M., Verbeke, K., Wang, J., Machiels, K., Sabino, J., Ferrante, M., Van Assche, G., Rutgeerts, P., & Raes, J. (2016) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjv203 · Cited by 311
Baunwall, S. M. D., Lee, M. M., Eriksen, M. K., Mullish, B. H., Marchesi, J. R., Dahlerup, J. F., & Hvas, C. L. (2020) · EClinicalMedicine · doi:10.1016/j.eclinm.2020.100642 · Cited by 300
“, 2014 [33] USA RCT Overall 20 14 (70%) 14 (70%) 18 (90%) 8¢0 54¢5 55¢0 + 4¢5 ¢¢ Low risk”
Fecal microbiota transplantation
Vindigni, S. M., & Surawicz, C. M. (2017) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2016.09.012 · Cited by 283
Universality of human microbial dynamics
Bashan, A., Gibson, T. E., Friedman, J., Carey, V. J., Weiss, S. T., Hohmann, E. L., & Liu, Y.-Y. (2016) · Nature · doi:10.1038/nature18301 · Cited by 270
“To address this question, we applied the DOC analysis to microbial samples of 17 subjects with recurrent Clostridium difficile infection (rCDI) and the same set of subjects after FMT 17 .”
InfluentialSelf-citationThe gut microbiota: A treasure for human health
Li, D., Wang, P., Wang, P., Hu, X., & Chen, F. (2016) · Biotechnology Advances · doi:10.1016/j.biotechadv.2016.08.003 · Cited by 261
Weingarden, A., González, A., Vázquez-Baeza, Y., Weiss, S., Humphry, G., Berg-Lyons, D., Knights, D., Unno, T., Bobr, A., Kang, J., et al. (2015) · Microbiome · doi:10.1186/s40168-015-0070-0 · Cited by 248
“EMPeror [29] was used for data visualization of BIOMformat [30] OTU tables.”
MethodStaley, C., Hamilton, M. J., Vaughn, B. P., Graiziger, C. T., Newman, K. M., Kabage, A. J., Sadowsky, M. J., & Khoruts, A. (2017) · American Journal of Gastroenterology · doi:10.1038/ajg.2017.6 · Cited by 244
Fecal microbiota transplantation as novel therapy in gastroenterology: A systematic review
Rossen, N. G. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i17.5359 · Cited by 242
Fecal Microbiota Transplantation: An Update on Clinical Practice
Kim, K. O., & Gluck, M. (2019) · Clinical Endoscopy · doi:10.5946/ce.2019.009 · Cited by 233
“The standard dose of FMT is specific to each institution or physician; however, about 50– 100 g of donor fecal material that has been diluted to 250–500 mL of infusate is most commonly used.(9,12,43,48) FMT can be administered either directly to the colon or from the upper gastrointestinal tract through capsule ingest…”
BackgroundIntestinal microbiota in early life and its implications on childhood health
Zhuang, L., Chen, H., Zhang, S., Zhuang, J., Li, Q., & Feng, Z. (2019) · Genomics, Proteomics & Bioinformatics · doi:10.1016/j.gpb.2018.10.002 · Cited by 219
“The fecal microbiota can be placed in patients by colonoscopy [179,180], nasogastric or nasoduodenal tubes [181], enemas [182], or oral capsules [183,184].”
BackgroundTowards the biogeography of prokaryotic genes
Coelho, L. P., Alves, R., del Río, Á. R., Myers, P. N., Cantalapiedra, C. P., Giner-Lamia, J., Schmidt, T. S., Mende, D. R., Orakov, A., Letunic, I., et al. (2022) · Nature · doi:10.1038/s41586-021-04233-4 · Cited by 215
Third-party fecal microbiota transplantation following allo-HCT reconstitutes microbiome diversity
DeFilipp, Z., Peled, J. U., Li, S., Mahabamunuge, J., Dagher, Z., Slingerland, A. E., Del Rio, C., Valles, B., Kempner, M. E., Smith, M., et al. (2018) · Blood Advances · doi:10.1182/bloodadvances.2018017731 · Cited by 211
“Early approaches to FMT for C difficile colitis administered liquid fecal inocula by invasive methods such as nasogastric intubation or endoscopy.(8,9) A novel approach to FMT administration is through third-party frozen, encapsulated inoculum, which can be delivered by the oral route.”
MethodSelf-citationDesign of synthetic human gut microbiome assembly and butyrate production
Clark, R. L., Connors, B. M., Stevenson, D. M., Hromada, S. E., Hamilton, J. J., Amador-Noguez, D., & Venturelli, O. S. (2021) · Nature Communications · doi:10.1038/s41467-021-22938-y · Cited by 204
Minkoff, N. Z., Aslam, S., Medina, M., Tanner‐Smith, E. E., Zackular, J. P., Acra, S. A., Nicholson, M. R., & Imdad, A. (2023) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013871.pub2 · Cited by 205
Orenstein, R., Dubberke, E., Hardi, R., Ray, A., Mullane, K., Pardi, D. S., & Ramesh, M. S. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/civ938 · Cited by 197
“A recent study of FMT capsules reported abdominal pain and bloating in 20%; 4 serious AEs and 2 deaths were felt to be unrelated to the product [12].”
BackgroundHota, S. S., Sales, V., Tomlinson, G., Salpeter, M. J., McGeer, A., Coburn, B., Guttman, D. S., Low, D. E., & Poutanen, S. M. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/ciw731 · Cited by 192
“A small randomized trial of FT by nasogastric route vs colonoscopy using a frozen inoculum reported overall CDI resolution in 90% of 20 treated patients [12].”
MethodFecal Transplants: What Is Being Transferred?
Bojanova, D. P., & Bordenstein, S. R. (2016) · PLOS Biology · doi:10.1371/journal.pbio.1002503 · Cited by 190
“Several studies compared the efficacy of frozen versus fresh stool on recurrent or refractory CDI and reported little to no difference [14,27,28].”
BackgroundThe gut microbiota and its interactions with cardiovascular disease
Xu, H., Wang, X., Feng, W., Liu, Q., Zhou, S., Liu, Q., & Cai, L. (2020) · Microbial Biotechnology · doi:10.1111/1751-7915.13524 · Cited by 186
A catalogue of 1,167 genomes from the human gut archaeome
Chibani, C. M., Mahnert, A., Borrel, G., Almeida, A., Werner, A., Brugère, J.-F., Gribaldo, S., Finn, R. D., Schmitz, R. A., & Moissl-Eichinger, C. (2021) · Nature Microbiology · doi:10.1038/s41564-021-01020-9 · Cited by 185
Adverse events in faecal microbiota transplant: a review of the literature
Baxter, M., & Colville, A. (2016) · Journal of Hospital Infection · doi:10.1016/j.jhin.2015.10.024 · Cited by 185
Youngster, I., Mahabamunuge, J., Systrom, H. K., Sauk, J., Khalili, H., Levin, J., Kaplan, J. L., & Hohmann, E. L. (2016) · BMC Medicine · doi:10.1186/s12916-016-0680-9 · Cited by 184
Self-citationLi, Y.-T., Cai, H.-F., Wang, Z.-H., Xu, J., & Fang, J.-Y. (2016) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13492 · Cited by 157
“However, a randomised, controlled pilot study concluded that nasogastric tube administration appeared to be as effective as colonscopic administration.(51) However, the number of patients in each group was only 10, indicating a weak study power.”
BackgroundChamberlain, R., & Lau, C. (2016) · International Journal of General Medicine · doi:10.2147/ijgm.s98280 · Cited by 177
Review article: the gut microbiome in inflammatory bowel disease—avenues for microbial management
McIlroy, J., Ianiro, G., Mukhopadhya, I., Hansen, R., & Hold, G. L. (2018) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14384 · Cited by 176
“frequent dosing and would simplify the design of placebo-controlled trials, though dose limitation may become a factor.(150)”
BackgroundSatokari, R., Mattila, E., Kainulainen, V., & Arkkila, P. E. T. (2015) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13009 · Cited by 156
“Recently, faecal microbiota transplantation (FMT) has been recognised as an effective treatment for rCDI.13, 16, 20, 21, 23, 28 In this study, we developed a simple and practical, one-step protocol for the preparation of frozen faecal inoculum for FMT and evaluated the efficacy of the frozen preparation in treating rC…”
BackgroundInfluentialTariq, R., Pardi, D. S., Bartlett, M. G., & Khanna, S. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciy721 · Cited by 175
Huttner, B. D., de Lastours, V., Wassenberg, M., Maharshak, N., Mauris, A., Galperine, T., Zanichelli, V., Kapel, N., Bellanger, A., Olearo, F., et al. (2019) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2018.12.009 · Cited by 174
Weingarden, A. R., Dosa, P. I., DeWinter, E., Steer, C. J., Shaughnessy, M. K., Johnson, J. R., Khoruts, A., & Sadowsky, M. J. (2016) · PLOS ONE · doi:10.1371/journal.pone.0147210 · Cited by 153
How to: establish and run a stool bank
Terveer, E. M., van Beurden, Y. H., Goorhuis, A., Seegers, J. F. M. L., Bauer, M. P., van Nood, E., Dijkgraaf, M. G. W., Mulder, C. J. J., Vandenbroucke-Grauls, C. M. J. E., Verspaget, H. W., et al. (2017) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2017.05.015 · Cited by 168
“However, later evidence showed that FMT with donor faeces from unrelated donors was as effective [5,15].”
BackgroundMethodBreakthroughs in the treatment and prevention of Clostridium difficile infection
Kociolek, L. K., & Gerding, D. N. (2016) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2015.220 · Cited by 167
Hirsch, B. E., Saraiya, N., Poeth, K., Schwartz, R. M., Epstein, M. E., & Honig, G. (2015) · BMC Infectious Diseases · doi:10.1186/s12879-015-0930-z · Cited by 150
“Resuspension of the bacteria in 15% glycerol for cryopreservation has been previously validated to retain clinical activity [25,75].”
BackgroundMethodFecal transplantation for treatment of inflammatory bowel disease
Imdad, A., Nicholson, M. R., Tanner-Smith, E. E., Zackular, J. P., Gomez-Duarte, O. G., Beaulieu, D. B., & Acra, S. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012774.pub2 · Cited by 164
Fecal microbiota transplantation beyond Clostridioides difficile infections
Wortelboer, K., Nieuwdorp, M., & Herrema, H. (2019) · eBioMedicine · doi:10.1016/j.ebiom.2019.05.066 · Cited by 163
Cheng, S., Ma, X., Geng, S., Jiang, X., Li, Y., Hu, L., Lǐ, J., Wang, Y., & Han, X. (2018) · mSystems · doi:10.1128/msystems.00137-18 · Cited by 162
“difficile after they received a transplant of a fecal microbiota suspension from healthy humans (35).”
BackgroundClostridioides difficile: diagnosis and treatments
Guery, B., Galperine, T., & Barbut, F. (2019) · BMJ · doi:10.1136/bmj.l4609 · Cited by 106
Keller, J. J., Ooijevaar, R. E., Hvas, C. L., Terveer, E. M., Lieberknecht, S. C., Högenauer, C., Arkkila, P., Sokol, H., Gridnyev, O., Mégraud, F., et al. (2021) · United European Gastroenterology Journal · doi:10.1177/2050640620967898 · Cited by 160
“53).(74) In addition, nasogastric administration is possible after pretreatment with proton pump inhibitors.”
BackgroundClostridioides difficile Infection
Guh, A. Y., & Kutty, P. K. (2018) · Annals of Internal Medicine · doi:10.7326/aitc201810020 · Cited by 159
Fecal Microbiota Transplantation: a Future Therapeutic Option for Obesity/Diabetes?
Aron‐Wisnewsky, J., Clément, K., & Nieuwdorp, M. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1180-z · Cited by 160
Fecal transplantation for treatment of inflammatory bowel disease
Imdad, A., Nicholson, M. R., Tanner-Smith, E. E., Zackular, J. P., Gomez-Duarte, O., Borromeo Beaulieu, D. M., & Acra, S. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012774 · Cited by 158
Stilling, R. M., Bordenstein, S. R., Dinan, T. G., & Cryan, J. F. (2014) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2014.00147 · Cited by 137
Costello, S. P., Conlon, M. A., Vuaran, M. S., Roberts-Thomson, I. C., & Andrews, J. M. (2015) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13366 · Cited by 141
Faecal microbiota transplantation for Clostridioides difficile: mechanisms and pharmacology
Khoruts, A., Staley, C., & Sadowsky, M. J. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-0350-4 · Cited by 155
Treating Obesity and Metabolic Syndrome with Fecal Microbiota Transplantation.
Marotz, C. A., & Zarrinpar, A. (2016) · PubMed Central · Cited by 151
Long-Term Safety and Efficacy of Fecal Microbiota Transplant in Active Ulcerative Colitis
Ding, X. L., Li, Q., Li, P., Zhang, T., Cui, B., Ji, G., Lü, X., & Zhang, F. (2019) · Drug Safety · doi:10.1007/s40264-019-00809-2 · Cited by 145
Fecal transplantation for treatment of inflammatory bowel disease
Imdad, A., Pandit, N. G., Zaman, M., Minkoff, N. Z., Tanner‐Smith, E. E., Gomez-Duarte, O. G., Acra, S. A., & Nicholson, M. R. (2023) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012774.pub3 · Cited by 143
Hui, W., Li, T., Liu, W., Zhou, C., & Gao, F. (2019) · PLoS ONE · doi:10.1371/journal.pone.0210016 · Cited by 140
RetractedMoayyedi, P., Yuan, Y., Baharith, H., & Ford, A. C. (2017) · Medical Journal of Australia · doi:10.5694/mja17.00295 · Cited by 125
Trubiano, J. A., Cheng, A. C., Korman, T. M., Röder, C., Campbell, A. J., May, M., Blyth, C. C., Ferguson, J., Blackmore, T., Riley, T. V., et al. (2016) · Internal Medicine Journal · doi:10.1111/imj.13027 · Cited by 128
Multiscale Evolutionary Dynamics of Host-Associated Microbiomes
Ferreiro, A., Crook, N., Gasparrini, A. J., & Dantas, G. (2018) · Cell · doi:10.1016/j.cell.2018.02.015 · Cited by 127
“A randomized controlled trial demonstrated resolution of recurring CDI in 94% of patients that received one or two FMTs from a healthy donor (van Nood et al., 2013), and other studies have shown similar success (Brandt et al., 2012; Ray et al., 2014; Rohlke et al., 2010; Youngster et al., 2014).”
Webb, B. J., Brunner, A., Ford, C. D., Gazdik, M. A., Petersen, F. B., & Hoda, D. (2016) · Transplant Infectious Disease · doi:10.1111/tid.12550 · Cited by 123
“This novel therapy appears to be highly effective in non-HSCT populations, with multiple studies reporting response rates approaching 90% (3, 9, 16).”
BackgroundDelivery routes for faecal microbiota transplants: Available, anticipated and aspired
Gulati, M., Singh, S. K., Corrie, L., Kaur, I. P., & Chandwani, L. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104954 · Cited by 121
Costello, S. P., Tucker, E. C., La Brooy, J., Schoeman, M. N., & Andrews, J. M. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/civ994 · Cited by 105
Ramai, D. (2018) · Annals of Gastroenterology · doi:10.20524/aog.2018.0328 · Cited by 93
“Inferences from randomized controlled trials (RCTs) are also limited, as those trials were not structured to investigate the donor-patient relationship and their outcomes (Table 1) [5,23-29].”
BackgroundInfluentialRamai, D., Zakhia, K., Fields, P. J., Ofosu, A., Patel, G., Shahnazarian, V., Lai, J., Dhaliwal, A., Reddy, M., & Chang, S. (2020) · Digestive Diseases and Sciences · doi:10.1007/s10620-020-06185-7 · Cited by 113
Wilson, B. C., Vatanen, T., Jayasinghe, T. N., Leong, K. S. W., Derraik, J. G. B., Albert, B. B., Chiavaroli, V., Svirskis, D. M., Beck, K. L., Conlon, C. A., et al. (2021) · Microbiome · doi:10.1186/s40168-021-01060-7 · Cited by 102
“117 118 Fecal microbiota transplantation procedure 119 Fecal microbiota was harvested from fresh donor stool and double encapsulated using a validated 120 protocol (Youngster et al., 2014).”
MethodFecal Microbial Transplantation and Its Potential Application in Cardiometabolic Syndrome
Leshem, A., Horesh, N., & Elinav, E. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01341 · Cited by 103
Influence of Environmental Factors in the Development and Outcomes of Inflammatory Bowel Disease.
Vedamurthy, A., & Ananthakrishnan, A. N. (2019) · Europe PMC (PubMed Central) · Cited by 101
Fecal microbial transplant via nasogastric tube for active pediatric ulcerative colitis
Suskind, D. L., Singh, N., Nielson, H., & Wahbeh, G. (2015) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0000000000000544 · Cited by 99
“We did not evaluate whether single FMT by NG tube in our pediatric patients with UC caused engraftment of donor microbiota or changed recipient intestinal microbiota diversity, as has been described previously with single-donor NG tube delivery of FMT for patients with recurrent C difficile infection (9).”
BackgroundProfiling Living Bacteria Informs Preparation of Fecal Microbiota Transplantations
Chu, N. D., Smith, M. B., Perrotta, A. R., Kassam, Z., & Alm, E. J. (2017) · PLoS ONE · doi:10.1371/journal.pone.0170922 · Cited by 98
“Members of all three genera are generally thought to be strictly anaerobic [28,32,40], suggesting that information on growth conditions alone may be insufficient to predict how bacterial taxa in complex communities will respond to stress.”
BackgroundSelf-citationNicco, C., Paule, A., Konturek, P. C., & Edeas, M. A. (2020) · Diseases · doi:10.3390/diseases8020009 · Cited by 98
“The use of capsule or enema is less invasive, does not require specialized, costly devices, and can be performed outside a care facility [11,42].”
BackgroundClostridium difficile Drug Pipeline: Challenges in Discovery and Development of New Agents
Jarrad, A. M., Karoli, T., Blaskovich, M. A. T., Lyras, D., & Cooper, M. A. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm5016846 · Cited by 97
Impacts of florfenicol on the microbiota landscape and resistome as revealed by metagenomic analysis
Zeng, Q., Liao, C., Terhune, J. S., & Wang, L. (2019) · Microbiome · doi:10.1186/s40168-019-0773-8 · Cited by 96
Bakker, G. J., & Nieuwdorp, M. (2017) · Microbiology Spectrum · doi:10.1128/microbiolspec.bad-0008-2017 · Cited by 60
Langdon, A. E., Schwartz, D. J., Bulow, C., Sun, X., Hink, T., Reske, K. A., Jones, C. R., Burnham, C. D., Dubberke, E. R., & Dantas, G. A. (2021) · Genome Medicine · doi:10.1186/s13073-021-00843-9 · Cited by 93
On the Origins and Control of Community Types in the Human Microbiome
Gibson, T. E., Bashan, A., Cao, H.-T., Weiss, S. T., & Liu, Y.-Y. (2016) · PLOS Computational Biology · doi:10.1371/journal.pcbi.1004688 · Cited by 82
“In scenario 3 we explored how the open-loop control methodology just presented could also be used to conceptually justify the success of FMT in treating patients with rCDI [20–22].”
BackgroundMethodHarris, E. V., de Roode, J. C., & Gerardo, N. M. (2019) · PLoS Pathogens · doi:10.1371/journal.ppat.1007891 · Cited by 90
An ecological framework to understand the efficacy of fecal microbiota transplantation
Xiao, Y., Angulo, M. T., Lao, S., Weiss, S. T., & Liu, Y.-Y. (2020) · Nature Communications · doi:10.1038/s41467-020-17180-x · Cited by 89
Zhou, C., Lehar, S. M., Gutierrez, J., Rosenberger, C. M., Ljumanovic, N., Dinoso, J. B., Koppada, N., Hong, K., Baruch, A., Carrasco‐Triguero, M., et al. (2016) · mAbs · doi:10.1080/19420862.2016.1229722 · Cited by 89
Corticosteroid-resistant immune-related adverse events: a systematic review
Daetwyler, E., Wallrabenstein, T., König, D., Cappelli, L. C., Naidoo, J., Zippelius, A., & Laubli, H. P. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-007409 · Cited by 89
Sokol, H., Galperine, T., Kapel, N., Bourlioux, P., Seksik, P., Barbut, F., Scanzi, J., Chast, F., Batista, R., Joly, F., et al. (2015) · Digestive and Liver Disease · doi:10.1016/j.dld.2015.08.017 · Cited by 91
van Beurden, Y. H., de Groot, P. F., van Nood, E., Nieuwdorp, M., Keller, J. J., & Goorhuis, A. (2017) · United European Gastroenterology Journal · doi:10.1177/2050640616678099 · Cited by 76
Fecal Microbiota Transplantation for the Management of Clostridium difficile Infection
Rao, K. K., & Young, V. B. (2015) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2014.11.009 · Cited by 87
Ross, C. L., Spinler, J. K., & Savidge, T. (2016) · Anaerobe · doi:10.1016/j.anaerobe.2016.05.006 · Cited by 86
Furuya-Kanamori, L., Doi, S. A. R., Paterson, D. L., Helms, S. K., Yakob, L., McKenzie, S. J., Garborg, K., Emanuelsson, F., Stollman, N., Kronman, M. P., et al. (2017) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000000511 · Cited by 76
Metadata
- Authors
- Youngster, I., Sauk, J., Pindar, C., Wilson, R. G., Kaplan, J. L., Smith, M. B., Alm, E. J., Gevers, D., Russell, G. H., & Hohmann, E. L.
- Affiliations
- Boston Children's Hospital (US)
- Harvard University (US)
- Massachusetts General Hospital (US)
- Broad Institute (US)
- Corresponding author
- Youngster, Ilan
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2014-04-23
- Volume
- 58
- Issue
- 11
- Pages
- 1515-1522
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- PMC
- PMC4017893
- OpenAlex
- W2146116383
- Cited by
- 467
- References
- 32
- Citations by year
- 2026: 7 · 2025: 15 · 2024: 31 · 2023: 22 · 2022: 24 · 2021: 35 · 2020: 37 · 2019: 51 · 2018: 47 · 2017: 57 · 2016: 53 · 2015: 61 · 2014: 27
- FWCI
- 46.23
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Clinical Infectious Diseases (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion, cc-by-nc-sa)
- Funders
- National Institutes of Health (UL1TR000170)
- National Institute of Allergy and Infectious Diseases (HHSN272200900018C)
- National Institute of Diabetes and Digestive and Kidney Diseases (P30DK043351)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Infectious Diseases › Clostridium difficile and Clostridium perfringens research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Keywords
- fecal microbiota transplantation, recurrent Clostridium difficile infection, unrelated donor, nasogastric tube administration, diarrhea resolution, health-related quality of life, antibiotic-refractory infection
- MeSH terms
- Adolescent, Adult, Aged, Aged, 80 and over, Biological Therapy, Child, Clostridium Infections, Colonoscopy, Diarrhea, Female, Humans, Intubation, Gastrointestinal, Male, Middle Aged, Pilot Projects, Surveys and Questionnaires, Recurrence, Clostridioides difficile, Treatment Outcome, Young Adult, Unrelated Donors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.